UY25798A1 - Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. - Google Patents

Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.

Info

Publication number
UY25798A1
UY25798A1 UY25798A UY25798A UY25798A1 UY 25798 A1 UY25798 A1 UY 25798A1 UY 25798 A UY25798 A UY 25798A UY 25798 A UY25798 A UY 25798A UY 25798 A1 UY25798 A1 UY 25798A1
Authority
UY
Uruguay
Prior art keywords
insulin sensitizer
pharmaceutical composition
modified release
thiazolidinadionic
release including
Prior art date
Application number
UY25798A
Other languages
English (en)
Inventor
Re Vincenzo
Skinner Janet Louise
Sauer Joseph
Muldoon William
Milosovich Susan Marie
Glinecke Robert
Original Assignee
Smithkline Beecham Plc
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824870.1A external-priority patent/GB9824870D0/en
Priority claimed from GBGB9912189.9A external-priority patent/GB9912189D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beckman Corp filed Critical Smithkline Beecham Plc
Publication of UY25798A1 publication Critical patent/UY25798A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica, la cual comprende un sensibilizador de insulina tiazolidinadiónico y un vehículo farmacéuticamente aceptable para el mismo, donde la misma está dispuesta para proporcionar una liberación modificada del sensibilizador de insulina, y el uso de tal composición en medicina para el tratamiento de diabetes mellitus tipo 2.
UY25798A 1998-11-12 1999-11-12 Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. UY25798A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824870.1A GB9824870D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912189.9A GB9912189D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Publications (1)

Publication Number Publication Date
UY25798A1 true UY25798A1 (es) 2000-12-29

Family

ID=26314667

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25798A UY25798A1 (es) 1998-11-12 1999-11-12 Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
UY25800A UY25800A1 (es) 1998-11-12 1999-11-15 Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY25800A UY25800A1 (es) 1998-11-12 1999-11-15 Procedimiento para preparar composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina.

Country Status (39)

Country Link
EP (3) EP1128827B1 (es)
JP (1) JP2002529505A (es)
KR (2) KR20060097140A (es)
CN (1) CN1289081C (es)
AP (2) AP1901A (es)
AR (2) AR023700A1 (es)
AT (1) ATE382352T1 (es)
AU (1) AU768578B2 (es)
BG (2) BG65444B1 (es)
BR (1) BR9915215A (es)
CA (1) CA2350659C (es)
CO (1) CO5190673A1 (es)
CY (1) CY1107909T1 (es)
CZ (1) CZ20011628A3 (es)
DE (1) DE69937898T2 (es)
DK (1) DK1128827T3 (es)
DZ (1) DZ2937A1 (es)
EA (3) EA200702648A1 (es)
EG (2) EG24463A (es)
ES (1) ES2299269T3 (es)
HK (1) HK1040909B (es)
HR (2) HRP20010342B1 (es)
HU (1) HUP0104307A3 (es)
ID (1) ID29344A (es)
IL (2) IL143003A0 (es)
MY (1) MY135973A (es)
NO (1) NO20012351L (es)
NZ (2) NZ526440A (es)
OA (1) OA11676A (es)
PE (1) PE20001428A1 (es)
PL (1) PL198717B1 (es)
PT (1) PT1128827E (es)
RS (1) RS50208B (es)
SI (1) SI1128827T1 (es)
SK (1) SK286937B6 (es)
TR (2) TR200503846T2 (es)
TW (2) TWI246920B (es)
UY (2) UY25798A1 (es)
WO (1) WO2000028990A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
EP1244468A2 (en) * 2000-01-07 2002-10-02 University Of Cincinnati Selective activation of a th1 or th2 lymphocyte regulated immune response
ATE380022T1 (de) * 2001-01-31 2007-12-15 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
DE60209824T2 (de) * 2001-12-21 2006-10-19 Smithkline Beecham Corp. Dosierschema für ppar-gamma-aktivatoren
MY139719A (en) * 2002-02-12 2009-10-30 Glaxo Group Ltd Oral dosage form for controlled drug release
WO2004006921A1 (ja) * 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited 被覆製剤の製造法
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
WO2004062577A2 (en) 2003-01-03 2004-07-29 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
BRPI0407074A (pt) 2003-01-29 2006-01-24 Takeda Pharmaceutical Método para produção de uma preparação revestida, preparação revestida, e, método para melhorar a dissolução do cloridreto de pioglitazona de uma preparação revestida com cloridreto de pioglitazona
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
CN103945832B (zh) * 2011-07-14 2017-03-29 能脑有限责任公司 用于脑能量分子延迟释放和持续释放的组合物，装置及方法
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
WO1989008650A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
HUT65619A (en) 1990-07-03 1994-07-28 Yamanouchi Pharma Co Ltd Process for producing bisheterocyclic compounds and pharmaceutical preparations containing them
KR930701420A (ko) 1990-08-23 1993-06-11 알렌 제이. 스피겔 혈당저하제로서의 하이드록시우레아 유도체
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
ES2161692T3 (es) 1991-04-11 2001-12-16 Upjohn Co Derivados de tiazolidindiona, produccion y uso de los mismos.
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (es) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
JPH07505647A (ja) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および２型糖尿病の治療におけるそれらの使用
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
RU2134686C1 (ru) 1992-07-03 1999-08-20 Смитклайн Бичам П.Л.С. Гетероциклическое соединение, или его таутомерная форма, и/или фармацевтически приемлемая соль, и/или фармацевтически приемлемый сольват, фармацевтическая композиция, снижающая содержание глюкозы в крови, способ лечения и/или профилактики гипергликемии
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3256841B2 (ja) * 1996-06-27 2002-02-18 武田薬品工業株式会社 ベンズアルデヒド化合物の製造法
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
WO1998042340A1 (en) * 1997-03-24 1998-10-01 Galderma Research & Development, S.N.C. Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Also Published As

Publication number Publication date
DK1128827T3 (da) 2008-04-28
DE69937898D1 (de) 2008-02-14
EA200601144A1 (ru) 2007-02-27
AP1901A (en) 2008-10-24
ATE382352T1 (de) 2008-01-15
EP1128827B1 (en) 2008-01-02
NO20012351D0 (no) 2001-05-11
EG22344A (en) 2002-12-31
HUP0104307A3 (en) 2003-12-29
AU768578B2 (en) 2003-12-18
DZ2937A1 (fr) 2004-03-15
ID29344A (id) 2001-08-23
CY1107909T1 (el) 2013-09-04
SK286937B6 (sk) 2009-07-06
PT1128827E (pt) 2008-03-10
EA200100540A1 (ru) 2001-10-22
KR20010073229A (ko) 2001-07-31
CA2350659A1 (en) 2000-05-25
CO5190673A1 (es) 2002-08-29
NZ511611A (en) 2003-10-31
TWI257305B (en) 2006-07-01
CN1289081C (zh) 2006-12-13
BG109893A (bg) 2008-11-28
AU1272900A (en) 2000-06-05
EP1815855A1 (en) 2007-08-08
CZ20011628A3 (cs) 2001-12-12
HUP0104307A2 (hu) 2002-07-29
HK1040909B (zh) 2008-08-01
CN1333683A (zh) 2002-01-30
EA200702648A1 (ru) 2008-10-30
ES2299269T3 (es) 2008-05-16
KR100732599B1 (ko) 2007-06-27
UY25800A1 (es) 2000-08-21
YU36401A (sh) 2004-05-12
IL143003A0 (en) 2002-04-21
BG65444B1 (bg) 2008-08-29
HK1040909A1 (en) 2002-06-28
EG24463A (en) 2009-07-16
SK6432001A3 (en) 2001-12-03
CA2350659C (en) 2009-06-09
HRP20010342A2 (en) 2002-06-30
DE69937898T2 (de) 2009-01-02
KR20060097140A (ko) 2006-09-13
JP2002529505A (ja) 2002-09-10
HRP20080117A2 (en) 2008-10-31
PE20001428A1 (es) 2001-02-08
AR023700A1 (es) 2002-09-04
AP2008004490A0 (en) 2008-06-30
NZ526440A (en) 2005-01-28
PL198717B1 (pl) 2008-07-31
TR200503846T2 (tr) 2007-01-22
TR200101337T2 (tr) 2001-11-21
OA11676A (en) 2005-01-12
PL348153A1 (en) 2002-05-06
MY135973A (en) 2008-07-31
AR023699A1 (es) 2002-09-04
TW200505436A (en) 2005-02-16
TWI246920B (en) 2006-01-11
IL183972A0 (en) 2007-10-31
HRP20010342B1 (en) 2008-04-30
BG105570A (en) 2002-02-28
EP1128827A1 (en) 2001-09-05
SI1128827T1 (sl) 2008-06-30
NO20012351L (no) 2001-07-04
EA007608B1 (ru) 2006-12-29
EP1917962A1 (en) 2008-05-07
WO2000028990A1 (en) 2000-05-25
BR9915215A (pt) 2001-07-31
RS50208B (sr) 2009-07-15

Similar Documents

Publication Publication Date Title
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
ES2150889T1 (es) Una combinacion de glibenclamida-clorhidrato para el tratamiento de la diabetes mellitus de tipo ii.
AR012998A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.
CL2009001899A1 (es) Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
ES2105926B1 (es) El uso de taxol para la fabricacion de una preparacion de infusion para el tratamiento del cancer.
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
SV2002000969A (es) Composicion parenteral reconstituible
AR025060A1 (es) Formulaciones farmaceuticas en capsulas de hidroxipropilmetilcelulosa
AR019724A2 (es) Composicion farmaceutica util para el tratamiento de diabetes mellitus y condiciones asociadas
AR008025A1 (es) Combinación farmacéutica de una tiazolidindiona y un secretagogo de insulina
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
MY138246A (en) Treatment of diabetes with thiazolidione and sulphonylurea.
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
ECSP993216A (es) Nueva composicion y uso ii
UY25801A1 (es) Procedimiento para preparar composiciones para el tratamiento de diabetes.
ECSP993215A (es) Nueva composicion y uso
ECSP982593A (es) Nuevo metodo de tratamiento vi
DE59813300D1 (de) Pharmazeutische zubereitungen
AR010343A1 (es) Uso de 17 beta-dihidroequilenina o una sal farmaceuticamente aceptable del ester de 17 beta-dihidroequilenina-3-sulfato para la manufactura de unmedicamento como antioxidante y composicion farmaceutica.
CO5160246A1 (es) Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias
AP1692A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent.
ECSP982591A (es) Nuevo metodo de tratamiento iv
ECSP982535A (es) Nuevo metodo de tratamiento (i)

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20101122